21 results
8-K
EX-10.2
EDSA
Edesa Biotech Inc
3 Nov 22
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
4:30pm
H4Z 1G3
Telephone: (514) 395-0337 or 1-877-525-0337
Facsimile: (514) 864-6381
(For privacy requests only)
Email: financementdessocietes
8-K
EX-10.1
EDSA
Edesa Biotech Inc
3 Nov 22
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
4:30pm
) 395-0337 or 1-877-525-0337
Facsimile: (514) 864-6381
(For privacy requests only)
Email: financementdessocietes@lautorite.qc.ca (For corporate
8-K
EX-10.1
3mq4i7h91zyytj
23 Mar 22
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:05pm
8-K
EX-1.1
ls4qfmpupf6clh5vjw
22 Nov 21
Entry into a Material Definitive Agreement
4:19pm
8-K/A
EX-1.1
f1sr6ew488f d8oz
26 Feb 21
Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares
4:10pm
8-K
EX-10.1
0qpwtaqtkchoqxmfv2f
3 Feb 21
Edesa Biotech Receives C$14 million for COVID-19 Study
8:00am
8-K
EX-1.1
0zj8y 8655
28 Sep 20
Entry into a Material Definitive Agreement
4:36pm
8-K
EX-10.3
4jdgyox
23 Apr 20
Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
4:20pm
8-K
EX-10.2
k33ota 60u7e
6 Jan 20
Edesa Biotech Announces $4.36 Million Registered Direct Offering
5:03pm
10-KT
j05hgi0htehyxu9b5
12 Dec 19
Annual report (with FYE transition)
4:55pm
DEFM14A
nkvcnx9pex33ln
18 Apr 19
Proxy related to merger
5:08pm
PREM14A
dt2iz
29 Mar 19
Preliminary proxy related to merger
4:18pm
8-K
EX-2.1
y4mp7zb5nmzej9h87 3u
8 Mar 19
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement
9:16am
DEFA14A
EX-2.1
phnheh
8 Mar 19
Additional proxy soliciting materials
9:14am
10-K
EX-10.12
19uj2p3n
14 Nov 14
Annual report
12:00am